Integra LifeSciences (NASDAQ:IART) Share Price Passes Above 200-Day Moving Average - Here's Why

Key Points

• Integra LifeSciences shares crossed above their 200-day moving average, reaching $17.08 before closing at $16.62, compared with the $14.35 long-term average.
• Analyst sentiment remains cautious: the stock has an average “Reduce” rating and a consensus price target of $18.86, although recent targets range from $18 to $25.
• The company beat quarterly expectations with adjusted EPS of $0.56 versus the $0.48 estimate and revenue of $418.76 million, while institutional investors own 84.78% of its shares.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $14.35 and traded as high as $17.08. Integra LifeSciences shares last traded at $16.62, with a volume of 559,667 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Truist Financial raised their price objective on Integra LifeSciences from $14.00 to $19.00 and gave the stock a "hold" rating in a research report on Thursday, July 16th. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating and set a $25.00 target price on the stock in a report on Thursday, June 18th. Wall Street Zen lowered shares of Integra LifeSciences from a "strong-buy" rating to a "buy" rating in a research report on Saturday, July 18th. Wells Fargo & Company raised their price target on shares of Integra LifeSciences from $15.00 to $18.00 and gave the stock an "equal weight" rating in a report on Thursday, July 30th. Finally, UBS Group began coverage on shares of Integra LifeSciences in a research report on Tuesday, July 28th. They set a "neutral" rating and a $19.00 price objective on the stock. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Reduce" and a consensus target price of $18.86.

Integra LifeSciences Trading Down 1.8%

The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -184.65, a PEG ratio of 0.87 and a beta of 1.21. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The business has a 50-day moving average of $17.89 and a 200-day moving average of $14.35.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The firm had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.46 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

A number of hedge funds have recently added to or reduced their stakes in the company. Paradigm Capital Management Inc. NY bought a new position in Integra LifeSciences during the second quarter valued at approximately $61,766,000. Rubric Capital Management LP grew its position in Integra LifeSciences by 58.4% in the second quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company's stock worth $90,233,000 after acquiring an additional 2,710,262 shares in the last quarter. California State Teachers Retirement System grew its position in Integra LifeSciences by 2,059.1% in the second quarter. California State Teachers Retirement System now owns 1,358,620 shares of the life sciences company's stock worth $24,401,000 after acquiring an additional 1,295,695 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Integra LifeSciences by 71.4% during the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company's stock worth $13,325,000 after purchasing an additional 589,408 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Integra LifeSciences during the 2nd quarter worth $8,723,000. Institutional investors and hedge funds own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source